Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 7/20 | 0.47 |
| ▸ | CA1 | P00915 | 7/20 | 0.47 |
| ▸ | CA2 | P00918 | 7/20 | 0.47 |
| ▸ | CA9 | Q16790 | 7/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9331881 | 0.98 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22939675 | 0.98 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL2805155 | 0.98 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL13788602 | 0.98 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL450913 | 0.98 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL23728804 | 0.98 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL35060 | 0.98 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL21113607 | 0.98 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22515370 | 0.98 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL30945310 | 0.98 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 713 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119564946-A | Azo calixarene-based broad-spectrum quantitative medicine-carrying acupuncture needle, and preparation method and application thereof | 天津中医药大学第一附属医院 | 2025-03-07 | — | — | CN | claimed |
| CN-119241380-A | Preparation method and application of clay mineral surface hydration inhibitor | 西南石油大学 | 2025-01-03 | — | — | CN | claimed |
| CN-118955953-A | Super-strain self-adhesive flexible hydrogel and preparation method and application thereof | 广东工业大学 | 2024-11-15 | — | — | CN | claimed |
| CN-116574081-B | Chlorogenic acid-Huang Qinsu conjugate and preparation method and application thereof | 江西省科学院应用化学研究所 | 2023-09-05 | — | — | CN | claimed |
| CN-116574081-A | Chlorogenic acid-Huang Qinsu conjugate and preparation method and application thereof | 江西省科学院应用化学研究所 | 2023-08-11 | — | — | CN | claimed |
| US-20230118911-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) FOR DEGRADATION OF AURORA A-KINASE | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2023-04-20 | — | — | US | claimed |
| CN-109456250-B | Thermal Activation Delayed Fluorescence (TADF) nano probe, preparation method thereof and application thereof in biological imaging | 哈尔滨医科大学 | 2022-03-04 | — | — | CN | claimed |
| CN-109456250-A | Hot activation delayed fluorescence (TADF) nano-probe and preparation method thereof and the application in bio-imaging | 哈尔滨医科大学 | 2019-03-12 | — | — | CN | claimed |
| CN-122036705-A | PROTAC compound of targeted PI3K alpha and preparation and application thereof | 三亚深海化合物资源中心 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036541-A | Amino acid-based ionizable lipid compound, and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2026-05-15 | — | — | CN | disclosed |
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12617905-B2 | Crosslinked alginic acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2026-05-05 | — | — | US | disclosed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-6114321-A | Porphyrin derivatives, pharmaceutical agents that contain the latter, and their use in photodynamic therapy and MRI diagnosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-09-05 | — | — | US | disclosed |
| US-5773612-A | VASOPRESSIN OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5594023-A | 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-01-14 | — | — | US | disclosed |
| EP-0687251-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995018105-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-07-06 | — | — | WO | disclosed |
| US-5053503-A | For joining antibodies and metallic radionuclides | CENTOCOR (US) | 1991-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118911-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) FOR DEGRADATION OF AURORA A-KINASE | CRBN, AURKC, AURKB | TDP1 3529/4885MAOA 4610/4885MAOB 3875/4885 |
| US-12617905-B2 | Crosslinked alginic acid | ALG1, ANXA6, HEXB | TDP1 1973/4885MAOA 726/4885MAOB 422/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | TDP1 3694/4885MAOA 1115/4885MAOB 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.